Development of an estimative model for the optimal tack coat dosage based on aggregate gradation of hot mix asphalt pavements

In this work the performance of tack coats on asphalt pavement layers is analysed. Adjustment models based on experimental measurements were implemented, relating surface layer macro-texture and aggregate content larger than 8 mm. The best fits were obtained with a Gompertz model, which follows the expected physical macro-texture changes outside the test range. Shear strength was analysed, through prediction curves of each evaluated tack coat dosage, with an optimum tack coat performance for aggregate contents larger than 8 mm between 45% and 50%, and no relevant influence of the tack coat dosage used.The authors would like to acknowledge the support provided by the Technologic Research Construction Group (GITECO) and the Group of Roads of Santander at Cantabria University for the development of tests and samples. We would also like to thank the company Emilio Bolado S.L. and the Society for the Development of Cantabria Region (SODERCAN) for the material provided, and the DID Research Department from the Austral University of Chile for the support

Chirality of the gamma-lactones formed by Fusarium poae inra 45

International audienc

MEDAQUARIVE. Rapport d'avancement des travaux

Le présent document marque un deuxième état d'avancement du programme MedAquaRive. Il fait état des différents bilans (chimie, biologie) in-situ effectués dans le réseau hydrographique du haut de l'Arc, et des résultats obtenus dans les essais d'évaluation toxicologique sur les algues et sur les macro-invertébrés benthiques. Compte tenu du contexte climatique régional, une partie des éléments exploités dans ce rapport font référence en majorité à données acquises pendant l'année hydrologique 2006-2007

Doravirine plus lamivudine two-drug regimen as maintenance antiretroviral therapy in people living with HIV: a French observational study

International audienceBackground: Two-drug regimens based on integrase strand transfer inhibitors (INSTIs) and boosted PIs have entered recommended ART. However, INSTIs and boosted PIs may not be suitable for all patients. We aimed to report our experience with doravirine/lamivudine as maintenance therapy in people living with HIV (PLWH) followed in French HIV settings.Methods: This observational study enrolled all adults who initiated doravirine/lamivudine between 1 September 2019 and 31 October 2021, in French HIV centres participating in the Dat'AIDS cohort. The primary outcome was the rate of virological success (plasma HIV-RNA < 50 copies/mL) at Week (W)48. Secondary outcomes included: rate of treatment discontinuation for non-virological reasons, evolution of CD4 count and CD4/CD8 ratio over follow-up.Results: Fifty patients were included, with 34 (68%) men; median age: 58 years (IQR 51-62), ART duration: 20 years (13-23), duration of virological suppression: 14 years (8-19), CD4 count: 784 cells/mm3 (636-889). Prior to switching, all had plasma HIV-RNA < 50 copies/mL. All but three were naive to doravirine, and 36 (72%) came from a three-drug regimen. Median follow-up was 79 weeks (IQR 60-96). Virological success rate at W48 was 98.0% (95% CI 89.4-99.9). One virological failure occurred at W18 (HIV-RNA = 101 copies/mL) in a patient who briefly discontinued doravirine/lamivudine due to intense nightmares; there was no resistance at baseline and no resistance emergence. There were three strategy discontinuations for adverse events (digestive disorders: n = 2; insomnia: n = 1). There was no significant change in CD4/CD8 ratio, while CD4 T cell count significantly increased.Conclusions: These preliminary findings suggest that doravirine/lamivudine regimens can maintain high levels of viral suppression in highly ART-experienced PLWH with long-term viral suppression, and good CD4+ T cell count

No barrier to care, yet disparities in the HIV care continuum in France: a nationwide population study

International audienceAbstract Objectives Even in an ‘optimal’ health system, patients’ characteristics may have an impact on their care. We investigated whether age, gender and place of birth have an impact in the HIV care continuum in France, a country with a universal free healthcare system. Methods We estimated differences in the 5 year restricted mean percentage of person-time spent (i) in care, (ii) receiving ART and (iii) on ART and virally suppressed among 2432 (30.2%) women, 3925 MSM (48.7%) and 1709 men who have sex with women (MSW; 21.2%) entering care in the Dat’AIDS French prospective cohort between 1 January 2013 and 31 December 2017. Trial registration: Clinicaltrials.gov reference NCT02898987. Results Men and women spent 85.6% and 82.8% of person-time on ART and 69.9% and 65% suppressed, respectively. MSM, MSW and women spent 86.9%, 82.6% and 82.8% of person-time on ART and 72.5%, 63.7% and 65% suppressed, respectively. Patients born in France (47%) and patients born abroad spent 87.9% and 81.9% of person-time on ART and 74.6% and 62.9% suppressed, respectively. Young men born abroad were found to spend the smallest person-time with non-detectable viral load (53% for MSW and 58.1% for MSM). Conclusions Despite free access to care and universal ART in France, disparities remain in the HIV continuum care across age, country of birth and way of HIV acquisition. Clinical and public health interventions targeting specific patients’ conditions are needed